Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión

DRUG2 trials

Sponsors

Swiss Group for Clinical Cancer Research, Hospital Universitario La Paz

Conditions

Metastatic castration-resistant prostate cancerNon-muscle invasive bladder cancer

Phase 2

SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial

RecruitingCTIS2024-512132-29-00

Swiss Group for Clinical Cancer ResearchMetastatic castration-resistant prostate cancer

Start: 2025-08-06Target: 100Updated: 2025-05-22

Phase 4

RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE UROTHELIAL CARCINOMA

RecruitingCTIS2024-512683-53-00

Hospital Universitario La PazNon-muscle invasive bladder cancer

Start: 2018-05-18Target: 312Updated: 2024-04-23